Dupilumab-话题@MedSci

#Dupilumab#

37篇内容 | 2446人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1282913, encodeId=879c1282913f6, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=J Asthma Allergy：SCIT+dupilumab治疗过敏性鼻炎是否优于单独的SCIT？, objectType=article, longId=216888, objectId=da9121688864, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da9121688864, replyNumber=0, likeNumber=81, createdTime=2021-09-11, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da9121688864, moduleTitle=J Asthma Allergy：SCIT+dupilumab治疗过敏性鼻炎是否优于单独的SCIT？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da9121688864)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282912, encodeId=e87a12829124d, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=AM J CLIN DERMATOL：使用Dupilumab的特异性皮炎患者无需开展实验室监测, objectType=article, longId=214637, objectId=d42a21463e4c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d42a21463e4c, replyNumber=0, likeNumber=87, createdTime=2021-07-24, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d42a21463e4c, moduleTitle=AM J CLIN DERMATOL：使用Dupilumab的特异性皮炎患者无需开展实验室监测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d42a21463e4c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282911, encodeId=49ae12829112a, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=Allergy：嗜酸细胞状态不影响Dupilumab的慢性鼻窦炎伴鼻息肉疗效 , objectType=article, longId=212981, objectId=6ed1212981b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ed1212981b9, replyNumber=0, likeNumber=106, createdTime=2021-06-22, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ed1212981b9, moduleTitle=Allergy：嗜酸细胞状态不影响Dupilumab的慢性鼻窦炎伴鼻息肉疗效 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ed1212981b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282910, encodeId=3dc0128291032, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=J Allergy Clin Immunol Pract：Dupilumab可改善中重度特应性皮炎成人的哮喘和鼻窦炎疗效, objectType=article, longId=207003, objectId=59f620e003bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59f620e003bf, replyNumber=0, likeNumber=79, createdTime=2021-02-11, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59f620e003bf, moduleTitle=J Allergy Clin Immunol Pract：Dupilumab可改善中重度特应性皮炎成人的哮喘和鼻窦炎疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59f620e003bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282909, encodeId=ef221282909d3, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=J Invest Dermatol：Dupilumab对IL-4Rα的阻断作用可降低特应性皮炎患者皮肤上金葡菌的定植并增加微生物的多样性, objectType=article, longId=199626, objectId=d462199626d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d462199626d8, replyNumber=0, likeNumber=105, createdTime=2020-08-19, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d462199626d8, moduleTitle=J Invest Dermatol：Dupilumab对IL-4Rα的阻断作用可降低特应性皮炎患者皮肤上金葡菌的定植并增加微生物的多样性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d462199626d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282908, encodeId=8bb41282908e2, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=慢性皮肤病及呼吸道疾病患者的福音：FDA批准Dupixent（dupilumab）300mg预填充笔, objectType=article, longId=196203, objectId=838b196203df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=838b196203df, replyNumber=0, likeNumber=51, createdTime=2020-06-22, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=838b196203df, moduleTitle=慢性皮肤病及呼吸道疾病患者的福音：FDA批准Dupixent（dupilumab）300mg预填充笔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=838b196203df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282907, encodeId=dcb1128290e2d, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=Gastroenterology：Dupilumab治疗嗜酸性食管炎, objectType=article, longId=180589, objectId=a40018058963, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a40018058963, replyNumber=0, likeNumber=63, createdTime=2019-10-08, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a40018058963, moduleTitle=Gastroenterology：Dupilumab治疗嗜酸性食管炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a40018058963)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282906, encodeId=f51f1282906ed, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=Lancet：Dupilumab治疗慢性鼻窦炎合并鼻息肉, objectType=article, longId=179940, objectId=a10a1e9940b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a10a1e9940b0, replyNumber=0, likeNumber=90, createdTime=2019-09-25, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a10a1e9940b0, moduleTitle=Lancet：Dupilumab治疗慢性鼻窦炎合并鼻息肉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a10a1e9940b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282905, encodeId=8b96128290539, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=Allergy：Dupilumab能够改善慢性鼻窦炎鼻息肉患者的生活质量, objectType=article, longId=176951, objectId=9cf11e6951aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9cf11e6951aa, replyNumber=0, likeNumber=85, createdTime=2019-08-07, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9cf11e6951aa, moduleTitle=Allergy：Dupilumab能够改善慢性鼻窦炎鼻息肉患者的生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9cf11e6951aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282904, encodeId=240f128290437, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=2019年美国皮肤病学会（AAD）年会：Dupixent（dupilumab）治疗控制不佳的特应性皮炎, objectType=article, longId=161554, objectId=0fcc16155489, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fcc16155489, replyNumber=0, likeNumber=74, createdTime=2019-03-04, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fcc16155489, moduleTitle=2019年美国皮肤病学会（AAD）年会：Dupixent（dupilumab）治疗控制不佳的特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fcc16155489)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282903, encodeId=f82e1282903ab, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , objectType=article, longId=161247, objectId=7cfc16124ea4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cfc16124ea4, replyNumber=0, likeNumber=64, createdTime=2019-02-28, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cfc16124ea4, moduleTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cfc16124ea4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282902, encodeId=d5cc128290272, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=2018年 ERS：Dupilumab显著改善中重度哮喘和合并症患者的症状, objectType=article, longId=149158, objectId=7a4f149158de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a4f149158de, replyNumber=0, likeNumber=66, createdTime=2018-09-21, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a4f149158de, moduleTitle=2018年 ERS：Dupilumab显著改善中重度哮喘和合并症患者的症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a4f149158de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282901, encodeId=52811282901f2, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=NEJM：Dupilumab治疗中重度不受控制哮喘的疗效显著, objectType=article, longId=138824, objectId=256913882481, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=256913882481, replyNumber=0, likeNumber=65, createdTime=2018-05-24, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=256913882481, moduleTitle=NEJM：Dupilumab治疗中重度不受控制哮喘的疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=256913882481)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282900, encodeId=b78b1282900e1, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=NEJM：Dupilumab对皮质激素依赖性重度哮喘患者的疗效显著, objectType=article, longId=138823, objectId=59661388231b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59661388231b, replyNumber=0, likeNumber=91, createdTime=2018-05-24, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59661388231b, moduleTitle=NEJM：Dupilumab对皮质激素依赖性重度哮喘患者的疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59661388231b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282899, encodeId=f6111282899b9, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=J Allergy Clin Immunol：Dupilumab在永久过敏性鼻炎和并发哮喘中的效果和安全性评估, objectType=article, longId=130110, objectId=5f4f130110bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f4f130110bf, replyNumber=0, likeNumber=64, createdTime=2018-02-15, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f4f130110bf, moduleTitle=J Allergy Clin Immunol：Dupilumab在永久过敏性鼻炎和并发哮喘中的效果和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f4f130110bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282898, encodeId=5313128289867, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=Lancet：Dupilumab联用糖皮质激素用于中度到重度特应性皮炎, objectType=article, longId=97953, objectId=a2209e953e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2209e953e7, replyNumber=0, likeNumber=0, createdTime=2017-05-07, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2209e953e7, moduleTitle=Lancet：Dupilumab联用糖皮质激素用于中度到重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2209e953e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282897, encodeId=2d3c128289eb4, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=NEJM：两项3期临床试验表明Dupilumab可有效改善特应性皮炎的症状, objectType=article, longId=79164, objectId=59efe9164ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59efe9164ca, replyNumber=0, likeNumber=54, createdTime=2016-10-04, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59efe9164ca, moduleTitle=NEJM：两项3期临床试验表明Dupilumab可有效改善特应性皮炎的症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59efe9164ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282896, encodeId=c51512828963b, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=FDA优先评审再生元和赛诺菲特应性皮炎药物dupilumab, objectType=article, longId=78916, objectId=8d8de89167d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d8de89167d, replyNumber=0, likeNumber=62, createdTime=2016-09-30, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d8de89167d, moduleTitle=FDA优先评审再生元和赛诺菲特应性皮炎药物dupilumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d8de89167d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282895, encodeId=3aef1282895e9, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=Lancet：Dupilumab治疗成人持续哮喘患者的疗效和安全性较好, objectType=article, longId=67221, objectId=299e6e2214f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=299e6e2214f, replyNumber=0, likeNumber=101, createdTime=2016-04-29, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=299e6e2214f, moduleTitle=Lancet：Dupilumab治疗成人持续哮喘患者的疗效和安全性较好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=299e6e2214f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282894, encodeId=f2291282894ae, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, objectTitle=JAMA：哮喘新药dupilumab还能显著治疗难治的慢性鼻窦炎和鼻息肉, objectType=article, longId=62963, objectId=b9aa629634e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9aa629634e, replyNumber=0, likeNumber=70, createdTime=2016-02-05, rootId=0, userName=zhyy88, userId=40be178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9aa629634e, moduleTitle=JAMA：哮喘新药dupilumab还能显著治疗难治的慢性鼻窦炎和鼻息肉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9aa629634e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Dupilumab

2020-05-29

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

J Asthma Allergy：SCIT+dupilumab治疗过敏性鼻炎是否优于单独的SCIT？

2021-09-11

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

AM J CLIN DERMATOL：使用Dupilumab的特异性皮炎患者无需开展实验室监测

2021-07-24

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

Allergy：嗜酸细胞状态不影响Dupilumab的慢性鼻窦炎伴鼻息肉疗效

2021-06-22

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

J Allergy Clin Immunol Pract：Dupilumab可改善中重度特应性皮炎成人的哮喘和鼻窦炎疗效

2021-02-11

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

J Invest Dermatol：Dupilumab对IL-4Rα的阻断作用可降低特应性皮炎患者皮肤上金葡菌的定植并增加微生物的多样性

2020-08-19

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

慢性皮肤病及呼吸道疾病患者的福音：FDA批准Dupixent（dupilumab）300mg预填充笔

2020-06-22

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

Gastroenterology：Dupilumab治疗嗜酸性食管炎

2019-10-08

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

Lancet：Dupilumab治疗慢性鼻窦炎合并鼻息肉

2019-09-25

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

Allergy：Dupilumab能够改善慢性鼻窦炎鼻息肉患者的生活质量

2019-08-07

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

2019年美国皮肤病学会（AAD）年会：Dupixent（dupilumab）治疗控制不佳的特应性皮炎

2019-03-04

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 

2019-02-28

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

2018年 ERS：Dupilumab显著改善中重度哮喘和合并症患者的症状

2018-09-21

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

NEJM：Dupilumab治疗中重度不受控制哮喘的疗效显著

2018-05-24

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

NEJM：Dupilumab对皮质激素依赖性重度哮喘患者的疗效显著

2018-05-24

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

J Allergy Clin Immunol：Dupilumab在永久过敏性鼻炎和并发哮喘中的效果和安全性评估

2018-02-15

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

Lancet：Dupilumab联用糖皮质激素用于中度到重度特应性皮炎

2017-05-07

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

NEJM：两项3期临床试验表明Dupilumab可有效改善特应性皮炎的症状

2016-10-04

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

FDA优先评审再生元和赛诺菲特应性皮炎药物dupilumab

2016-09-30

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

Lancet：Dupilumab治疗成人持续哮喘患者的疗效和安全性较好

2016-04-29

zhyy88 (审核中...)

前往app查看评论内容

#Dupilumab#

JAMA：哮喘新药dupilumab还能显著治疗难治的慢性鼻窦炎和鼻息肉

2016-02-05

科室
- - 订阅+
  - 更多科室
工具
服务